CorMedix Inc

CRMD is entrenched in a Stage 4 decline with a clear sequence of lower highs and lower lows. Short-term trend and EMAs are sloping downward, and price is extended below moving averages without signs of exhaustion. The medium-term bias remains bearish, unsupported by any mean-reversion eligibility, justifying an immediate sell initiation into resistance at the declining EMA regime.

• ↑Q1 2026 net revenue $127.4M, up 226% YoY, led by DefendCath
• ↑FY26 revenue guidance raised to $325–345M from $300–320M
• ↓80% of shipments concentrated with U.S. Renal Care, posing client risk